Human antibody BD-218 has broad neutralizing activity against concerning variants of SARS-CoV-2Article Published on 2023-02-012023-07-11 Journal: International journal of biological macromolecules [Category] COVID19(2023년), [키워드] neutralizing antibody SARS-CoV-2. [DOI] 10.1016/j.ijbiomac.2022.12.120 PMC 바로가기
Neutralizing Antibody Responses Among Residents and Staff of Long-Term Care Facilities in the State of New Jersey During the First Wave of the COVID-19 PandemicArticle Published on 2023-02-012023-07-10 Journal: Journal of community health [Category] COVID19(2023년), [키워드] antibody duration Long-term care facility neutralizing antibody SARS-CoV-2 Vaccine response. [DOI] 10.1007/s10900-022-01142-z PMC 바로가기
Immunoglobulin germline gene polymorphisms influence the function of SARS-CoV-2 neutralizing antibodiesArticle Published on 2023-01-102023-07-11 Journal: Immunity [Category] COVID19(2023년), [키워드] copy-number variation immunoglobulin allelic diversity neutralizing antibody SARS-CoV-2 Single-nucleotide polymorphism. [DOI] 10.1016/j.immuni.2022.12.005 PMC 바로가기
High titers of neutralizing antibodies in the blood fail to eliminate SARS-CoV-2 viral RNA in the upper respiratory tractArticle Published on 2023-01-012023-07-10 Journal: Journal of medical virology [Category] COVID19(2023년), [키워드] neutralizing antibody vaccination viral RNA-positive retest. [DOI] 10.1002/jmv.28219 PMC 바로가기
Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infectionArticle Published on 2022-12-272023-07-10 Journal: Journal of Travel Medicine [Category] COVID19(2023년), [키워드] Anti-S1-IgA mRNA vaccines neutralizing antibody SRBD-IgM waning. [DOI] 10.1093/jtm/taac130 PMC 바로가기
Symptomatic and Asymptomatic SARS-CoV-2 Infection and Follow-up of Neutralizing Antibody LevelsArticle Published on 2022-12-202023-07-11 Journal: Biomedical and environmental sciences : BES [Category] COVID19(2023년), [키워드] Asymptomatic neutralizing antibody SARS-CoV-2 symptomatic. [DOI] 10.3967/bes2022.139 PMC 바로가기
Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Article Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 비임상, 진단, 치료기술, 치료제, [키워드] acute respiratory syndrome Beta Blood caused clinically Concentration coronavirus COVID-19 creatine phosphokinase CT-P63 deaths declining Delta demonstrated detectable dose double-blind evaluated groups healthy volunteer Immunity in vitro in vivo Infection Infectious virus lung monoclonal monoclonal antibody morbidity and mortality mutated variant Neutralizing Neutralizing activity neutralizing antibody neutralizing antibody. omicron pandemic parallel-group participant peaked phase Placebo placebo-controlled Preclinical prevalent Prophylactic Randomized reduced respiratory tract Safe SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants of concern Serious Adverse Events significantly single ascending dose study drug TEAE titre Tolerability Transgenic mouse treated Treatment treatment-emergent adverse event vaccination variants variants of SARS-CoV-2 wild-type [DOI] 10.1080/22221751.2022.2117094 PMC 바로가기
Evaluation of the T cell and B cell response following the administration of COVID-19 vaccines in KoreaArticle Published on 2022-12-012023-07-10 Journal: Journal of microbiology, immunology, and infection [Category] COVID19(2023년), [키워드] booster COVID-19 Interferon-gamma (IFN-γ) neutralizing antibody vaccine. [DOI] 10.1016/j.jmii.2022.09.004 PMC 바로가기
Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants코로나바이러스 질병 재조합 소단위 백신의 세 번째 용량으로 이종 부스팅은 다양한 중증 급성 호흡기 증후군 코로나바이러스 2 변이체에 대한 중화 항체 및 T 세포 면역을 증가시킵니다Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Analysis Anti-RBD IgG anti-S booster vaccination CD4+ T cell components composite pattern coronavirus coronavirus disease COVID-19 COVID-19 vaccinations COVID-19 vaccine dose effective epitope Epitopes evaluated Evidence help Heterologous heterologous boosting homologous Humoral immunity Immune escape Immunity immunization strategy immunological in some inactivated Inactivated vaccine increase magnitude NAb NAbs natural infection Neutralizing Neutralizing antibodies neutralizing antibody neutralizing capacity omicron pandemic prime-boost strategy produced RBD IgG respiratory subunit Subunit vaccine Subunit vaccine. T cell T cell response T cells titre vaccination Vaccination strategies Vaccination strategy Vaccine Vaccine-induced immunity variant variants of concern waned [DOI] 10.1080/22221751.2022.2048969 PMC 바로가기 [Article Type] Article
A SARS-CoV-2 vaccine based on conjugation of SARS-CoV-2 RBD with IC28 peptide and mannanArticle Published on 2022-12-012022-11-15 Journal: International journal of biological macromolecules [Category] COVID19(2023년), SARS, 진단, [키워드] ACE2 adjuvant Antibody titer Antigen antigenicity Bacterial cause cellular immunity COVID-19 COVID-19 pandemic cytokine develop domain E. coli effective effective vaccine elicit elicited expected expressed feasibility humoral IFN-γ IL-10 IL-5 IMPROVE Interaction Ligand mannan neutralization neutralizing antibody organs peptide polysaccharide RBD RBD-specific IgG SARS-CoV-2 SARS-CoV-2 RBD SARS-CoV-2 spike protein SARS-CoV-2 vaccine SARS-CoV-2. sera severe respiratory disease Th2-type Toxicity Vaccine Vaccine development viral infection virus [DOI] 10.1016/j.ijbiomac.2022.09.180 PMC 바로가기